NeuCyte

NeuCyte is a private, pre-revenue biotech founded in 2015 and based in Sunnyvale, California, with a core focus on neurological diseases. Its primary asset is the SynFire® platform, which produces homogeneous, high-functioning iPSC-derived neurons, astrocytes, and microglia for use in phenotypic screening and target-based drug discovery. The company operates with a hybrid business model, pursuing internal drug discovery programs while offering its platform and cells for strategic partnerships to external biopharma clients. NeuCyte is at a pre-clinical stage, utilizing its technology to identify novel therapeutic candidates and de-risk the early-stage neuroscience R&D process.

Proprietary SynFire® platform for generating homogeneous, high-functioning induced pluripotent stem cell (iPSC)-derived neural cells (neurons, astrocytes, microglia) for disease modeling, phenotypic screening, target validation, and compound assessment. Integrates electrophysiology, high-content imaging, and genomic analyses.

NeuCyte competes with other iPSC-focused companies (e.g., Fujifilm Cellular Dynamics, Axol Bioscience), CROs offering neural cell services, and large pharma internal efforts. Differentiation relies on the claimed superior functionality and purity of its SynFire® cells and its integrated assay capabilities.